Discordance of HER2 between primary tumors and lymph node metastatic lesions in invasive breast cancer
Main Article Content
Abstract
Background
Breast cancer therapy is mostly influenced by the type and molecular subtype, especially in the case of human epidermal growth factor receptor 2 (HER2) status, where HER2-positive patients will receive anti-HER2 therapy. HER2 status is obtained from HER2 immunohistochemistry examination which can be performed on primary breast tumors or lymph node metastatic lesions. This study aimed to determine the concordance of HER2 status between primary tumors and lymph node metastatic lesions in invasive breast cancer.
Methods
A cross-sectional study was conducted involving 30 invasive breast cancer patients. HER2 immunohistochemistry examination was carried out on both the primary tumor and lymph node metastatic lesions. The Cohen κ coefficient was used to analyse the data.
Results
The concordance rate for HER2 was 86.67%. Thirteen cases were concordantly HER2-negative in primary breast cancer (BC) and nodal metastases, and 13 cases were HER2-positive in both primary and metastatic tumors. Changes in HER2 status between primary BC and corresponding synchronous metastases were observed in four (4.72%) cases. One of the discordant cases was HER2-negative in the primary tumor and HER2-positive in the metastases, while three cases were HER2-positive in the primary breast cancer and HER2- negative in the metastases.
Conclusion
There is a discordance of HER2 status between the primary tumor and lymph node metastases in invasive breast cancer patients. It is necessary to evaluate the HER2 status of the primary tumor and metastases simultaneously. Such an evaluation is recommended for better prognosis and survival.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers (Basel). 2021;13:4287. doi:10.3390/cancers13174287.
Union for International Cancer Control Globocan. GLOBOCAN 2020: new global cancer Data. UICC; 2020.
International Agency for Research on Cancer World Health Organization. Global Cancer Observatory. Indonesia. Lyon, France: International Agency for Research on Cancer; 2020.
Badan Penelitian dan Pengembangan Kesehatan -. Laporan Provinsi DI Yogyakarta Riskesdas 2018. [Report of the Special Region of Yogyakarta Basic Health Research 2018.] Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2019. Indonesian.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. doi: 10.1016/S1470-2045(21)00288-6.
Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res 2020;10:1045-67.
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9. doi: 10.3322/caac. 21388.
Li MH, Hou CL, Wang C, Sun AJ. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women. Pathol Res Pract 2016;212:252-7. doi: 10.1016/j.prp.2015.11.019.
Sutthipongsupa T, Wongchansom K, Wuttipanich P, Charoenpitakchai M. A comparison study of molecular classification of primary invasive breast carcinoma and corresponding metastatic carcinoma in axillary lymph nodes by immunohistochemistry. Asian Arch Pathol 2020;2:20-32.
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276-82.
Ieni A, Barresi V, Caltabiano R, et al. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. Onco Targets Ther 2014;7:1267-72. doi: 10.2147/OTT.S65294.
Cai M, Li M, Lv H, et al. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases. BMC Cancer 2023;23:656. doi: 10.1186/s12885-023-11134-4.
Almstedt K, Krauthauser L, Kappenberg F, et al. Discordance of HER2-Low between primary tumors and matched distant metastases in breast cancer. Cancers (Basel) 2023;15:1413. doi: 10.3390/cancers15051413.
Valent A, Penault-Llorca F, Cayre A, Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Cancer Genet 2013;206:37-41. doi: 10.1016/ j.cancergen.2012.12.001.
Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 2020;54:34-44. doi: 10.4132/jptm. 2019.11.03.
Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nucl Med 2016;57:1523-8. doi: 10.2967/jnumed.115.172031.
Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel) 2023;15:1987. doi:10.3390/cancers15071987.
Widiana IK, Irawan H. Clinical and subtypes of breast cancer in Indonesia. Asian Pac J Cancer Care 2020;5:281-5. doi: 10.31557/apjcc.2020.5.4. 281-285.
Mogica JP, Tang H, Liang Y, et al. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: a single institution experience and review of the literature. Breast 2023;72:103586. doi: 10.1016/ j.breast.2023.103586.
Canadian Cancer Society. Targeted therapy drugs for HER2-positive breast cancer. Toronto, Canada: Canadian Cancer Society;2025.
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023;22:101. doi: 10.1038/s41573-022-00579-0.
Peralta-Castillo G, Maffuz-Aziz A, Sierra-Murguía M, Rodriguez-Cuevas S. Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients. Revista de Senología y Patología Mamaria J Senol Breast Dis 2020;33:137-44. doi: 10.1016/j.senol.2020.06.004.